Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DB-1311 in Combination with BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
2025-523895-22-00Phase 2Authorised
- Sponsor
- Duality Biotherapeutics
- Start
- May 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC), Cervical Cancer (CC), melanoma and 3 more comparing DB-1311 + BNT327 with DB-1311 + DB-1305 (2 arms). Primary endpoints: Number of participants with Dose Limiting Toxicities (DLTs), Treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs) in Part 1 and 2 more. Planned start May 2026; status: authorised.
02
Drugs
db-1311pumitamigDB-1305
03
Conditions
non-small cell lung cancer (NSCLC)Cervical Cancer (CC)melanomahepatocellular carcinoma (HCC)ovarian cancer
Beyond the preview
Go deeper on 2025-523895-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523895-22-00.